MUC1 is a membrane-bound glycoprotein that belongs to the mucin family. It is involved in cell adhesion and intracellular signaling. Aberrant expression of MUC1 has been observed in different ...
WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies published “Effective CAR T cell targeting of a MUC1 cleavage product” in the Journal for ImmunoTherapy of ...
Nonmyeloablative conditioning with mesenchymal stem cell transplantation for type 1 diabetis mellitus. Background: MUC1, a glycoprotein overexpressed by breast, intestinal, pancreatic, and gastric ...
MUC1 is a mucin protein overexpressed and abnormally glycosylated in many epithelial cancers. Although it is considered a potential target for vaccine development, its effectiveness is limited by its ...
A phase II study of the DNA plasmid-based vaccine STEMVAC in patients with metastatic triple-negative breast cancer (mTNBC). This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...
PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...
Antibody-drug conjugates (ADCs) are therapeutics that combine an antibody with a cytotoxic payload via a chemical linker to specifically target certain cells. Tumor-associated mucin-1 (TA-MUC1) is a ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results